Autoinjectors Market

1
Autoinjectors Market
The global autoinjectors market is anticipated to
grow at a CAGR of 16.9 during the forecast
period with its market size reaching USD 4.5
billion by 2024. Due to the prevalence of chronic
and lifestyle-related diseases, the increasing
incidence of anaphylaxis, and the development in
technology, the market is rising at a
considerable pace. Due to the benefits of
disposable autoinjectors, such as handiness, less
likelihood of contamination, and ease of use,
the industry has seen a strong demand for
disposable autoinjectors in the coming years.
By Product, the autoinjector market is
categorized into prefilled and fillable
injectors. Prefilled injectors hold the larger
share in the market and it is predicted that the
product category will also grow at a faster rate
during the forecast period. By design, the market
is categorized into standardized and customized
injectors. Standardized design of injectors is
the majorly sold category, whereas the market for
customized design injectors will witness the
higher growth during the forecast period. By
type, the market is subdivided into disposable
and reusable autoinjectors. The disposable
segment is expected to grow at a faster rate
during the forecast period in the market. By
therapy, the market is subdivided multiple
sclerosis, anaphylaxis, rheumatoid arthritis,
diabetes and others. Rheumatoid arthritis segment
is expected to grow at the fastest rate in the
market due increasing occurrence of rheumatoid
arthritis, globally. The key growth factors for
the market of autoinjectors are the growing
prevalence of chronic and lifestyle-related
illnesses, increasing number of regulatory
approvals, technology improvement and design
development, increasing medical attention and
patient propensity to self-administration,
mounting self-medication practise, and promising
reimbursements and government support.
2
The growth of the market for autoinjectors is
also facilitated by the patent expiry of
biologics, novel formulations and revolutionary
drug delivery systems, coupled with the
discovery and improvement of biological drugs,
increased healthcare spending, increased
incidence of anaphylaxis and accessibility of
generic varieties of autoinjectors. Recent
News In December 2016, Mylan N.V. launched the
authorized generic for EpiPen, as an
autoinjector. Competitive Insights Abbvie,
Ypsomed, Consort Medical, Johnson Johnson,
Mylan, Becton, Dickinson and Company, Amgen,
Haselmeier, ELI Lilly, Owen Mumford, Scandinavian
Health Limited and Antares Pharma are the key
players offering autoinjectors.
VynZ Research Call 91-996-028-8381 Toll-Free
(U.S. and Canada) 1-888-253-3960 Email
enquiry_at_vynzresearch.com Web https//www.vynzrese
arch.com Connect with Us LinkedIn Facebook
Twitter